Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pampa Metals Corp. V.PM


Primary Symbol: C.PM Alternate Symbol(s):  PMMCF

Metals & Mining Industrial Metals & Minerals
Pampa Metals is a CSE listed copper porphyry exploration company whose flagship project is the Piuquenes Copper-Gold-Silver Porphyry Project in San Juan Province, Argentina. Notable historic intervals at Piuquenes Central include 413.5m @ 0.47% Cu and 0.52 g/t Au (0.87% CuEq)* and 558.2m @ 0.38% Cu, 0.42 g/t Au, and 2.4 g/t Ag (0.73% CuEq)* (5 Dec 2023 News Release).


CSE:PM - Post by User

Pampa Metals Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by mayorkghon Apr 29, 2016 12:19pm
77 Views
Post# 24825784

Prism Q1/F16 results

Prism Q1/F16 resultsGood growth. Margins should improve in next few quarters. 

Prism Medical Q1/F16 Results – Top Line Beats, EBITDA Meets
 
Rating: Buy – Target: $12.00; Price: $9.15
Nick Agostino, CFA, MBA, P.Eng., Special Situations Analyst (AgostinoN@lb-securities.ca; 416-865-5967)
Impact: Neutral.
Sales beat offset by lower EBITDA margin resulting in in line EBITDA. As such we lower F2016 margins and look for more meaningful margins expansion in F2017.
Sales of $14.7M above our $13.3M est. on Canada sales beat. Organic sales growth ~8% excluding favourable F/X and acquisition contributions. Adjusted EBITDA at $1.5M in line with our estimate; margin 10.3% vs. 11.2% est. U.S. sales of $9.6M, up 9% YoY but flat excl. F/X, inline on strong homecare/institutional demand offsetting deferred hospital / acute sales; Canada sales of $5.1M beat our $3.6M estimate due to Angel acquisition growth. Dividend + M&A consuming cash. Net debt at $15.5M with net debt /LTM EBITDA at still reasonable 2.5x, flat QoQ. Continued M&A activity may result in increased debt; available credit at $8M.
Reiterate Buy, $12.00 TP based on 8x F2017E EV/EBITDA; stock currently trades at 7.6x NTM EV/EBITDA.
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities